GH Research PLC (NASDAQ:GHRS – Get Free Report)’s stock price passed above its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of $21.47 and traded as high as $22.13. GH Research shares last traded at $21.50, with a volume of 345,103 shares changing hands.
Analyst Ratings Changes
GHRS has been the subject of several recent analyst reports. Guggenheim upped their target price on shares of GH Research from $34.00 to $40.00 and gave the stock a “buy” rating in a research report on Friday, August 7th. Wells Fargo & Company started coverage on GH Research in a research note on Monday, July 27th. They issued an “overweight” rating and a $44.00 price target for the company. HC Wainwright reissued a “buy” rating on shares of GH Research in a research note on Monday, August 10th. Weiss Ratings reissued a “sell (d-)” rating on shares of GH Research in a report on Thursday, October 15th. Finally, Cantor Fitzgerald lifted their price objective on shares of GH Research from $35.00 to $40.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. Ten research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, GH Research has a consensus rating of “Moderate Buy” and a consensus price target of $45.00.
View Our Latest Stock Report on GH Research
GH Research Stock Up 3.8%
The stock has a market capitalization of $1.48 billion, a price-to-earnings ratio of -21.50 and a beta of 1.32. The business has a 50-day simple moving average of $24.21 and a two-hundred day simple moving average of $21.47.
GH Research (NASDAQ:GHRS – Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.23) EPS for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.06. On average, analysts forecast that GH Research PLC will post -1.20 EPS for the current year.
Hedge Funds Weigh In On GH Research
Large investors have recently made changes to their positions in the business. Braidwell LP acquired a new position in shares of GH Research in the 2nd quarter worth approximately $5,571,000. Troluce Capital Advisors LLC lifted its stake in GH Research by 165.4% during the first quarter. Troluce Capital Advisors LLC now owns 990,472 shares of the company’s stock valued at $13,926,000 after purchasing an additional 617,260 shares during the last quarter. Squarepoint Ops LLC acquired a new stake in GH Research during the second quarter valued at approximately $495,000. Renaissance Technologies LLC bought a new stake in GH Research during the first quarter worth approximately $290,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new stake in GH Research during the third quarter worth approximately $82,000. Institutional investors own 56.90% of the company’s stock.
About GH Research
GH Research plc is a clinical-stage biopharmaceutical company focused on developing novel therapies for psychiatric and neurological disorders. The company is headquartered in Dublin, Ireland, and conducts research and clinical development activities through its proprietary pipeline of psychedelic-based medicines.
Its lead program, GH001, is an investigational inhaled formulation of mebufotenin, also known as 5-MeO-DMT. GH Research has studied GH001 in patients with treatment-resistant depression, with the aim of developing a rapidly acting treatment that may provide meaningful improvements following a short course of administration.
Featured Stories
- Five stocks we like better than GH Research
- Phillips 66 Posts Strong Earnings But the Stock Doesn’t Care
- NXP Semiconductors Falls After Strong Earnings—Is the Sell-Off Overdone?
- GE Vernova’s Reservations Are Turning Into Real Orders—But the Market Still Wants More.
- Where’s the Beef? Trian-Led Buyout Proposal Values Wendy’s at $1.4B, But Is It Enough?
Receive News & Ratings for GH Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GH Research and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png){kind=logo}
